治疗便秘型肠易激综合征新药:钠/氢交换蛋白3抑制剂tenapanor  

Tenapanor:a novel inhibitor of sodium/hydrogen exchanger 3 for treatment of constipative irritable bowel syndrome

作　　者：夏博[1] 王芳[2] 李增军[3] XIA Bo;WANG Fang;LI Zeng-jun(General Surgery,the People’s Hospital of Linqu,Linqu SHANDONG 262600,China;Pharmacy Intravenous Admixture Services,the People’s Hospital of Linqu,Linqu SHANDONG 262600,China;Gastrointestinal Surgery,Shandong Tumor Hospital,Ji-nan SHANDONG 250117,China)

机构地区：[1]临朐县人民医院普外科,山东临朐262600 [2]临朐县人民医院静脉用药配置中心,山东临朐262600 [3]山东省肿瘤医院胃肠外科,山东济南250117

出　　处：《中国新药与临床杂志》2020年第10期596-599,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：便秘型肠易激综合征是一种常见的功能性胃肠道疾病。tenapanor是一种新型的钠/氢交换蛋白3抑制剂,由Ardelyx公司开发,于2017年9月由美国食品和药物管理局(FDA)批准上市,用于治疗和缓解便秘型肠易激综合征的成年患者。临床试验表明,tenapanor可缓解腹胀和腹痛,明显改善患者的生活质量。最常见的不良反应为腹泻。Constipative irritable bowel syndrome is a common functional gastrointestinal disease.Tenapanor is a new type of sodium/hydrogen exchanger 3 inhibitor developed by Ardelyx and approved by the U.S.Food and Drug Administration(FDA)for marketing in September 2017.It is used to treat and relieve adult patients with constipative irritable bowel syndrome.Clinical trials have shown that tenapanor can relieve abdominal distension and abdominal pain and significantly improve the quality of life of patients.A common adverse reaction is diarrhea.

关 键 词：tenapanor 肠易激综合征 便秘 交换蛋白 抑制剂 

分 类 号：R971[医药卫生—药品]